Navigation Links
QRxPharma Granted Additional US Patent on MoxDuo®
Date:5/23/2012

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.  This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.

"This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma's MoxDuo opioid products for the treatment of acute and chronic pain," said Dr. John Holaday, Managing Director and Chief Executive Officer.  "This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year."

The original composition of matter patent granted by the USPTO (U.S. Patent No. 6,310,072) covers the combination of morphine and oxycodone and provides coverage until 2016.  The newly issued patent is directed to a method of treatment of pain using MoxDuo's composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023.  Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

In April, QRxPharma announced the successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.  The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... and NEW YORK , May 27, ... - Over 70% Indonesian men (80 million) are ... annually due to smoking-related conditions; of these, 6% are ... vehicles in Jakarta do not ... is the fourth most populous country in ...
(Date:5/27/2015)... RUTHERFORD, N.J. , May 27, 2015  Cambrex Corporation ... Sargen , Executive Vice President and Chief Financial Officer, will ... 3, 2015 at 8:00 a.m. EDT in New ... and slide presentation can be accessed from the Cambrex website ... & Presentations", and a replay will be available for 90 ...
(Date:5/27/2015)... , May 27, 2015  Novartis will ... in 21 medicines and 11 investigational compounds across ... American Society of Clinical Oncology (ASCO) Annual Meeting, ... European Hematology Association (EHA), June 11-14. Data will ... cancer types, including melanoma, lung, breast, kidney and ...
Breaking Medicine Technology:Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 2Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 3Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 2Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 3Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 5Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 6Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 7Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 8
(Date:5/27/2015)... Iowa (PRWEB) May 27, 2015 With ... away, a poll conducted during the "ACA - Controlling ... poll participants, 75% are currently in the process of ... over 15% were confidently prepared for the reporting mandates. ... shown during the webinar, those who are currently vetting ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Decorview ... North America, is offering free design advice to homeowners ... environment. , “Light pollution caused by streetlights, outdoor ... a restless night’s sleep, said Kim Rush, VP of ... numerous cities across North America with recently installed LED ...
(Date:5/27/2015)... Louisville, KY (PRWEB) May 27, 2015 ... or worse because of lack of compliance documentation or ... a recycler in Miami, a propane gas company in ... doling out fines for incidents and accidents due to ... System (LMS) is proud to introduce the new ...
(Date:5/27/2015)... National Harbor, MD (PRWEB) May 27, 2015 ... ) will attend this year’s conference of the American ... 17-20 at the Gaylord National Resort. MCA’s booth is ... Largest Annual Gathering in Immigration Law.” MCAads.com, a regular ... a family meeting” as they welcome current clients to ...
(Date:5/27/2015)... FL (PRWEB) May 27, 2015 A. ... plastic surgeon announces the addition of UltraShape® , ... Syneron Candela, to his Tampa Plastic Surgery Center. ... destruction, UltraShape is the first and only non-invasive body ... precisely target subcutaneous fat, without harming the surrounding tissue, ...
Breaking Medicine News(10 mins):Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:Decorview Helps Homeowners Combat Light Pollution 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 2Health News:New Supervisor Feature Streamlines HR Compliance Reporting and Documentation 3Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 3Health News:Tampa Plastic Surgery Center Delivers A Better Way To A Better Body 2Health News:Tampa Plastic Surgery Center Delivers A Better Way To A Better Body 3
... the University of Wisconsin-Madison have identified dozens of clues ... ,The researchers identified nearly 40 genes that, ... the parasite from forming an infection in the brains ... of promising targets for developing drugs that could block ...
... brand ambassadors of India. But they could also prove a ... case of Thirumurthy Nakka Boomaiah , 35 and hailing ... ,He has been sentenced to 69 days in ... London to Philadelphia and assaulting flight attendants. But he has ...
... Michigan patients will have a new -- virtually pain ... Joseph Mercy Health System (SJMHS) announced today it will ... System on Wednesday, June 6th. ,This advanced ... body, including previously inoperable tumors, with astounding accuracy and ...
... The Seattle-based Infectious Disease Research Institute (IDRI) and ... entered into two research and development agreements ... Leishmaniasis and Leprosy, two 'neglected diseases' targeted by ... using Chembio's patented Dual Path immunoassay test platform ...
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... A psychologist at the University College London has designed a ... can be distracted. ,Professor Nilli Lavie claims that ... tool during the recruitment process, and may be beneficial in ... ,"When you are easily distracted, you are more liable ...
Cached Medicine News:Health News:Mutant Parasites, Unable to Infect Hosts, Highlight Virulence Genes 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 3Health News:Individuals Distraction can Be Measured by a Computer Based Test 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: